Cara Therapeutics (CARA) Misses Q2 EPS by 1c
Cara Therapeutics (NASDAQ: CARA) reported Q2 EPS of ($0.25), $0.01 worse than the analyst estimate of ($0.24).
For earnings history and earnings-related data on Cara Therapeutics (CARA) click here.
Cara Therapeutics (NASDAQ: CARA) reported Q2 EPS of ($0.25), $0.01 worse than the analyst estimate of ($0.24).
For earnings history and earnings-related data on Cara Therapeutics (CARA) click here.